J
Julio Cesar Teixeira
Researcher at State University of Campinas
Publications - 84
Citations - 6815
Julio Cesar Teixeira is an academic researcher from State University of Campinas. The author has contributed to research in topics: Cervical cancer & Cervical intraepithelial neoplasia. The author has an hindex of 23, co-authored 73 publications receiving 6304 citations. Previous affiliations of Julio Cesar Teixeira include Universidade Federal do Rio Grande do Sul.
Papers
More filters
Journal ArticleDOI
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial
Diane M. Harper,Eduardo L. Franco,Cosette M. Wheeler,Daron G. Ferris,D. G. Jenkins,Anne Schuind,Toufik Zahaf,Bruce L. Innis,Paulo Naud,Newton Sérgio de Carvalho,Cecilia Roteli-Martins,Julio Cesar Teixeira,Mark M. Blatter,A. Korn,Wim Quint,Gary Dubin +15 more
TL;DR: The bivalent HPV vaccine was efficacious in prevention of incident and persistent cervical infections with HPV-16 and HPV-18, and associated cytological abnormalities and lesions.
Journal ArticleDOI
Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women.
Jorma Paavonen,Paulo Naud,Jorge Salmerón,Cosette M. Wheeler,Song-Nan Chow,D Apter,Henry C Kitchener,Xavier Castellsagué,Julio Cesar Teixeira,S R Skinner,James Hedrick,Unnop Jaisamrarn,Genara Limson,Suzanne M. Garland,Anne Szarewski,Barbara Romanowski,Fred Y. Aoki,Tino F. Schwarz,Willy Poppe,Franz X. Bosch,David Jenkins,Karin Hardt,Toufik Zahaf,Dominique Descamps,Frank Struyf,Matti Lehtinen,Gary Dubin +26 more
TL;DR: The HPV- 16/18 AS04-adjuvanted vaccine showed high efficacy against CIN2+ associated with HPV-16/18 and non-vaccine oncogenic HPV types and substantial overall effect in cohorts that are relevant to universal mass vaccination and catch-up programmes.
Journal ArticleDOI
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
Matti Lehtinen,Jorma Paavonen,Cosette M. Wheeler,Unnop Jaisamrarn,Suzanne M. Garland,Xavier Castellsagué,S. Rachel Skinner,Dan Apter,Paulo Naud,Jorge Salmerón,Song Nan Chow,Henry C Kitchener,Julio Cesar Teixeira,James Hedrick,Genara Limson,Anne Szarewski,Barbara Romanowski,Fred Y. Aoki,Tino F. Schwarz,Willy Poppe,Newton Sérgio de Carvalho,Maria Julieta V Germar,Klaus Peters,Adrian Mindel,Philippe De Sutter,F. Xavier Bosch,Marie Pierre David,Dominique Descamps,Frank Struyf,Gary Dubin +29 more
TL;DR: End-of-study results show excellent vaccine efficacy against CIN3+ and AIS irrespective of HPV DNA in the lesion, suggesting population-based vaccination that incorporates the HPV-16/18 vaccine and high coverage of early adolescents might have the potential to substantially reduce the incidence of cervical cancer.
Journal ArticleDOI
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
Cosette M. Wheeler,Xavier Castellsagué,Suzanne M. Garland,Anne Szarewski,Jorma Paavonen,Paulo Naud,Jorge Salmerón,Song Nan Chow,D Apter,Henry C Kitchener,Julio Cesar Teixeira,S. Rachel Skinner,Unnop Jaisamrarn,Genara Limson,Barbara Romanowski,Fred Y. Aoki,Tino F. Schwarz,Willy Poppe,F. Xavier Bosch,Diane M. Harper,Warner K. Huh,Karin Hardt,Toufik Zahaf,Dominique Descamps,Frank Struyf,Gary Dubin,Matti Lehtinen +26 more
TL;DR: Data from the end-of-study analysis of PATRICIA show cross-protective efficacy of the HPV-16/18 vaccine against four oncogenic non-vaccine HPV types-HPV-33, HPV-31, HPV -45, and HPV-51-in different trial cohorts representing diverse groups of women.
Journal ArticleDOI
Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years.
Barbara Romanowski,de Borba Pc,Paulo Naud,Cecilia Roteli-Martins,De Carvalho Ns,Julio Cesar Teixeira,Fred Y. Aoki,Brian Ramjattan,Shier Rm,Somani R,Barbier S,Mark M. Blatter,Chambers C,Daron G. Ferris,Stanley A. Gall,Guerra Fa,Diane M. Harper,James Hedrick,Henry Dc,A. Korn,Kroll R,Anna-Barbara Moscicki,Rosenfeld Wd,Sullivan Bj,Thoming Cs,Stephen K. Tyring,Cosette M. Wheeler,Gary Dubin,Anne Schuind,Toufik Zahaf,Greenacre M,Sgriobhadair A +31 more
TL;DR: The findings show excellent long-term efficacy, high and sustained immunogenicity, and favourable safety of the HPV-16/18 AS04-adjuvanted vaccine up to 6.4 years.